Equillium Inc
NASDAQ:EQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Daeryuk Can Co Ltd
KOSDAQ:004780
|
KR |
|
N
|
NeoPharm Co Ltd
KOSDAQ:092730
|
KR |
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
Alamos Gold Inc
TSX:AGI
|
CA |
|
Logitech International SA
NASDAQ:LOGI
|
CH |
|
Acutus Medical Inc
OTC:AFIB
|
US |
|
Electrolux AB
OTC:ELRXF
|
SE |
|
Silver Elephant Mining Corp
TSX:ELEF
|
CA |
|
I
|
Innoprise Plantations Bhd
KLSE:INNO
|
MY |
|
GE Vernova Inc
MIL:1GEV
|
US |
|
K
|
Knowmerce Corp
KOSDAQ:473980
|
KR |
|
V
|
Versatile Creative Bhd
KLSE:VERSATL
|
MY |
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
AU |
|
C
|
Centuria Industrial Reit
ASX:CIP
|
AU |
|
P
|
Progressive Path Group Holdings Ltd
HKEX:1581
|
HK |
|
S
|
Starcore International Mines Ltd
OTC:SHVLF
|
CA |
|
SRJ Technologies Group PLC
ASX:SRJ
|
JE |
|
Columbus A/S
CSE:COLUM
|
DK |
|
R
|
R Stahl AG
XHAM:RSL2
|
DE |
|
Australian Silica Quartz Group Ltd
ASX:ASQ
|
AU |
|
Marsden Maritime Holdings Ltd
NZX:MMH
|
NZ |
|
Gke Corporation Ltd
SGX:595
|
SG |
|
Wereldhave NV
AEX:WHA
|
NL |
Equillium Inc
Research & Development
Equillium Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Research & Development
-$12.8m
|
CAGR 3-Years
40%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Research & Development?
Research & Development
-12.8m
USD
Based on the financial report for Dec 31, 2025, Equillium Inc's Research & Development amounts to -12.8m USD.
What is Equillium Inc's Research & Development growth rate?
Research & Development CAGR 5Y
9%
Over the last year, the Research & Development growth was 66%. The average annual Research & Development growth rates for Equillium Inc have been 40% over the past three years , 9% over the past five years .
